Shuttle Pharmaceuticals Holdings, Inc. - רווח נקי למניה (EPS TTM) SHPH

The success of Shuttle Pharmaceuticals (SHPH) depends on clinical test results and medical center support. The annual EPS TTM growth trajectory on the GURU.Markets chart reflects current dynamics, where 94.30 serves as the base parameter value. The company's prospects rely on the scalability of patents for oncology centers, while the synthesis of radiosensitizers is ensured by the sterility of contract sites in strict accordance with testing schedules.

Experienced investors utilize sector benchmarking to distinguish fundamental leaders from laggards. This metric measures the annual change in net earnings per share over a rolling period, reflecting the efficiency of capital generation. For Shuttle Pharmaceuticals (SHPH), which focuses on academic alliances in oncology, this calculation reveals financial resilience during the early testing phase. Analyzing the TTM YoY earnings per share growth rate allows for an assessment of the company's growth pace relative to the industry. Such an approach minimizes the risk of overpaying for an asset.